GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Beneish M-Score

Scinopharm Taiwan (TPE:1789) Beneish M-Score : -2.82 (As of Mar. 30, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.82 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Scinopharm Taiwan's Beneish M-Score or its related term are showing as below:

TPE:1789' s Beneish M-Score Range Over the Past 10 Years
Min: -3.12   Med: -2.74   Max: -2.07
Current: -2.82

During the past 13 years, the highest Beneish M-Score of Scinopharm Taiwan was -2.07. The lowest was -3.12. And the median was -2.74.


Scinopharm Taiwan Beneish M-Score Historical Data

The historical data trend for Scinopharm Taiwan's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Beneish M-Score Chart

Scinopharm Taiwan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.07 -2.80 -2.07 -2.22 -2.82

Scinopharm Taiwan Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -2.25 -2.72 -2.37 -2.82

Competitive Comparison of Scinopharm Taiwan's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Beneish M-Score falls into.


;
;

Scinopharm Taiwan Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Scinopharm Taiwan for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7522+0.528 * 0.9999+0.404 * 0.9748+0.892 * 1.0691+0.115 * 0.9493
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8912+4.679 * -0.034461-0.327 * 1.0482
=-2.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was NT$654 Mil.
Revenue was 1036.476 + 724.223 + 762.359 + 883.226 = NT$3,406 Mil.
Gross Profit was 377.146 + 278.988 + 290.763 + 353.313 = NT$1,300 Mil.
Total Current Assets was NT$6,608 Mil.
Total Assets was NT$11,943 Mil.
Property, Plant and Equipment(Net PPE) was NT$4,576 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$488 Mil.
Selling, General, & Admin. Expense(SGA) was NT$518 Mil.
Total Current Liabilities was NT$768 Mil.
Long-Term Debt & Capital Lease Obligation was NT$620 Mil.
Net Income was 97.342 + 27.103 + 74.882 + 140.023 = NT$339 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 254.643 + 74.941 + 36.918 + 384.411 = NT$751 Mil.
Total Receivables was NT$813 Mil.
Revenue was 1123.164 + 659.588 + 754.901 + 648.43 = NT$3,186 Mil.
Gross Profit was 457.675 + 231.478 + 282.944 + 243.892 = NT$1,216 Mil.
Total Current Assets was NT$6,381 Mil.
Total Assets was NT$11,722 Mil.
Property, Plant and Equipment(Net PPE) was NT$4,578 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$461 Mil.
Selling, General, & Admin. Expense(SGA) was NT$544 Mil.
Total Current Liabilities was NT$729 Mil.
Long-Term Debt & Capital Lease Obligation was NT$570 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(654.188 / 3406.284) / (813.451 / 3186.083)
=0.192053 / 0.255314
=0.7522

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1215.989 / 3186.083) / (1300.21 / 3406.284)
=0.381656 / 0.381709
=0.9999

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6608.09 + 4576.414) / 11942.738) / (1 - (6380.608 + 4577.59) / 11721.586)
=0.063489 / 0.065127
=0.9748

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3406.284 / 3186.083
=1.0691

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(461.167 / (461.167 + 4577.59)) / (488.281 / (488.281 + 4576.414))
=0.091524 / 0.096409
=0.9493

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(518.143 / 3406.284) / (543.825 / 3186.083)
=0.152114 / 0.170688
=0.8912

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((620.342 + 767.682) / 11942.738) / ((570.231 + 729.453) / 11721.586)
=0.116223 / 0.11088
=1.0482

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(339.35 - 0 - 750.913) / 11942.738
=-0.034461

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Scinopharm Taiwan has a M-score of -2.82 suggests that the company is unlikely to be a manipulator.


Scinopharm Taiwan Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines